SAB Biotherapeutics, Inc.
SABS
$1.79
$0.03992.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.10% | -41.09% | -45.96% | 78.01% | -347.97% |
| Total Depreciation and Amortization | -18.74% | -8.38% | -46.83% | 110.15% | -4.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 197.81% | 158.46% | 65.53% | -155.49% | 1,903.85% |
| Change in Net Operating Assets | -189.89% | 696.16% | 109.49% | -549.09% | 71.41% |
| Cash from Operations | -51.50% | 18.47% | 28.21% | 20.05% | -160.20% |
| Capital Expenditure | 44.77% | -91.05% | 59.33% | -90.13% | 20.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 991.96% | -109.34% | 136.09% | -- | -- |
| Cash from Investing | 909.54% | -110.27% | 135.78% | -46,084.39% | -66.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 57.77% | -157.27% | -1.98% | 13.92% | -101.40% |
| Issuance of Common Stock | -- | -- | -100.00% | -99.97% | 2,485,704.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 63.61% | 58.96% | -- | -- |
| Cash from Financing | 132.19% | -110.00% | 18.61% | -100.58% | 48,308.84% |
| Foreign Exchange rate Adjustments | -707.79% | 67.84% | 200.00% | -256.35% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.62% | -351.58% | 107.54% | -178.56% | 1,112.16% |